This eye-opening session will be presented this October 29th at the 4th CannaGrow Expo in Denver.
Dr. Zacariah L Hildenbrand will cover the latest scientific discoveries from the collaboration between C4 Laboratories and the University of Texas at Arlington, and will touch on the discovery of novel cannabis molecules, as well as the characterization of various cannabis chemotypes as a function of individual cannabinoid and terpene profiles.
Dr. Zacariah L. Hildenbrand received his bachelors of science and Ph.D. degrees from the University of Texas at El Paso, where he also played on the men’s intercollegiate golf team. Dr. Hildenbrand’s doctoral research focused on the molecular architecture involved in hormone-dependent cancers and was awarded the best doctoral dissertation in the College of Science for the year 2010. Dr. Hildenbrand continued his training as a post-doctoral research fellow at the University of Texas Southwestern Medical Center in Dallas where he contributed to the development of a novel therapy for the treatment of chronic myeloid leukemia; a blood-borne cancer that afflicts small children.
Dr. Hildenbrand has published more than 30 peer-reviewed scientific journal articles and textbook chapters, and has presented his research throughout North and South America. As the Chief Scientific Officer of C4 Laboratories in Mesa, Arizona, Dr. Hildenbrand is focused on educating the general public about the scientific merits of cannabis, as well as developing innovative cannabis-based therapies. Dr. Hildenbrand enjoys new research challenges that carry deep social significance and he is driven to provide solutions and find more efficient treatments for those struggling with illness.
See more about sessions coming to CannaGrow at CannaGrowExpo.com